Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
Acadia ( ACAD ) Q2 Revenue Rises 9%
Acadia Pharmaceuticals ( NASDAQ:ACAD ) , a neuroscience-focused biopharma company behind treatments for central nervous system diseases, reported its earnings for Q2 2025 on August 6, 2025. The most notable news was a slight beat on both GAAP earnings and revenue, driven by ongoing growth in its ...
Acadia Pharmaceuticals ( ACAD ) Tops Q2 Earnings and Revenue Estimates
Acadia (ACAD) delivered earnings and revenue surprises of +14.29% and +1.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Adaptive Biotechnologies ( ADPT ) Reports Q2 Loss, Beats Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +29.17% and +18.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?
CPRX gears up to report Q2 results as Firdapse sales rise, Agamree grows, and Fycompa faces a post-patent dip.
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.
Sarepta to Report Q2 Earnings: What's in Store for the Stock?
SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.
GMAB vs. ACAD: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR ( GMAB Quick QuoteGMAB - ) and Acadia Pharmaceuticals ( ACAD Quick QuoteACAD - ) . But which of these two stocks offers value investors a better bang for their buck right ...
Acadia Pharmaceuticals ( ACAD ) Expected to Beat Earnings Estimates: Should You Buy?
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note.
KMDA or ACAD: Which Is the Better Value Stock Right Now?
KMDA vs. ACAD: Which Stock Is the Better Value Option?
Is First Trust NYSE Arca Biotechnology ETF ( FBT ) a Strong ETF Right Now?
Smart Beta ETF report for ...
KMDA vs. ACAD: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Kamada ( KMDA Quick QuoteKMDA - ) or Acadia Pharmaceuticals ( ACAD Quick QuoteACAD - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look ...
JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory - ACADIA Pharmaceuticals ( NASDAQ:ACAD )
Court ruling secures Nuplazid's 34 mg formulation patent protection through 2038. JPMorgan hikes Acadia target from $26 to $30, citing strong patent outlook. Get access to the leaderboards pointing to tomorrow's biggest stock movers. In May, the U.S.
Why Is Acadia ( ACAD ) Up 26.1% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GSK or ACAD: Which Is the Better Value Stock Right Now?
GSK vs. ACAD: Which Stock Is the Better Value Option?
ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent
Acadia stock jumps 27% after winning a key patent case for Nuplazid, which will protect the drug's U.S. sales from generic erosion till 2038.
These Analysts Boost Their Forecasts On Acadia Pharmaceuticals - ACADIA Pharmaceuticals ( NASDAQ:ACAD )
ACADIA Pharmaceuticals Inc ACAD announced a favorable court ruling on Friday. The U.S. District Court for the District of Delaware upheld the validity and found infringement of Acadia's '721 formulation patent for NUPLAZID ( pimavanserin ) , a treatment for Parkinson's Disease Psychosis.
Netflix To $1,220? Here Are 10 Top Analyst Forecasts For Monday - Archer-Daniels-Midland ( NYSE:ADM ) , ACADIA Pharmaceuticals ( NASDAQ:ACAD )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Needham raised ACADIA Pharmaceuticals Inc. ACAD price target from $27 to $30.
Acadia Pharmaceuticals ( ACAD ) Stock Explodes 26% After Patent Court Victory - ACADIA Pharmaceuticals ( NASDAQ:ACAD )
ACADIA Pharmaceuticals stock jumped 26.4% Friday afternoon. Shares gained following a favorable court ruling. Discover the top trade setups and strategies beating the S&P this year -live this Wednesday at 6 PM ET. Reserve your free spot now.
Evolv Technologies, Quantum Computing, ACADIA Pharmaceuticals And Other Big Stocks Moving Higher On Friday - Archer Aviation ( NYSE:ACHR ) , ACADIA Pharmaceuticals ( NASDAQ:ACAD )
U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Friday. Shares of Evolv Technologies Holdings, Inc. EVLV rose sharply during Friday's session after the company announced preliminary first-quarter financial results. The company said it expects revenue growth of 40%+ in the ...
Acadia Pharmaceuticals ( ACAD ) Tops Q1 Earnings and Revenue Estimates ( Revised )
Acadia (ACAD) delivered earnings and revenue surprises of 10% and 1.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
ACAD reports encouraging first-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
Acadia Pharmaceuticals ( ACAD ) Tops Q1 Earnings and Revenue Estimates
Acadia (ACAD) delivered earnings and revenue surprises of 10% and 1.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
DENTSPLY SIRONA to Post Q1 Earnings: What's in Store for the Stock?
XRAY is likely to have faced a tough first quarter with Byte's revenue loss, weak U.S. equipment demands and implant pressures.
Analysts Estimate Fortrea Holdings Inc. ( FTRE ) to Report a Decline in Earnings: What to Look Out for
Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
Earnings Preview: Acadia Pharmaceuticals ( ACAD ) Q1 Earnings Expected to Decline
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia ( ACAD ) Stock Jumps 6.1%: Will It Continue to Soar?
Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Alector Provides Executive Leadership Update - Alector ( NASDAQ:ALEC )
--Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role-- SOUTH SAN FRANCISCO, Calif., March 28, 2025 ( GLOBE NEWSWIRE ) -- Alector, Inc.
Alector Provides Executive Leadership Update
--Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer ...
Why Is Acadia ( ACAD ) Down 11.1% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating hyperphagia in PWS patients.
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?
Axsome's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. The recent FDA nod for Symbravo also bodes well.
Acadia Pharmaceuticals ( ACAD ) Q4 Earnings Lag Estimates ( Revised )
Acadia (ACAD) delivered earnings and revenue surprises of -10.53% and 1.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth ( Revised )
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.
Acadia Pharmaceuticals ( ACAD ) Q4 Earnings Lag Estimates
Acadia (ACAD) delivered earnings and revenue surprises of -10.53% and 1.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals ( ACAD ) Stock?
Investors need to pay close attention to ACADIA Pharmaceuticals (ACAD) stock based on the movements in the options market lately.
Blueprint Medicines ( BPMC ) Reports Q4 Loss, Misses Revenue Estimates
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -12.86% and 0.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the First Trust NYSE Arca Biotechnology ETF ( FBT ) ?
Sector ETF report for ...
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals ( Revised )
Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals
Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.
Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide - ACADIA Pharmaceuticals ( NASDAQ:ACAD ) , Aptorum Gr ( NASDAQ:APM )
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday. The Dow traded down 0.26% to 42,461.52 while the NASDAQ fell 0.91% to 19,308.99. The S&P 500 also fell, dropping, 0.55% to 5,874.24.
Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet - Aptorum Gr ( NASDAQ:APM ) , ACADIA Pharmaceuticals ( NASDAQ:ACAD )
U.S. stocks traded slightly lower midway through trading, with the Nasdaq Composite falling around 50 points on Tuesday. The Dow traded down 0.05% to 42,554.24 while the NASDAQ fell 0.23% to 19,441.37. The S&P 500 also fell, dropping, 0.12% to 5,899.74. In trading on Tuesday, utilities shares ...
Acadia Pharmaceuticals, FTAI Aviation And Other Big Stocks Moving Higher On Tuesday - ACADIA Pharmaceuticals ( NASDAQ:ACAD ) , Almacenes Exito ( NYSE:EXTO )
U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Tuesday. Shares of ACADIA Pharmaceuticals Inc. ACAD rose sharply during Tuesday's session. Acadia Pharmaceuticals will replace Independent Bank Group in S&P SmallCap 600, effective prior to opening of trading on ...
Acadia ( ACAD ) Down 2.9% Since Last Earnings Report: Can It Rebound?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Implied Volatility Surging for ACADIA Pharmaceuticals ( ACAD ) Stock Options
Investors need to pay close attention to ACADIA Pharmaceuticals (ACAD) stock based on the movements in the options market lately.
ACAD Signs License Deal With Saniona for Rights to Neurology Drug
Acadia signs a $610 million exclusive global license agreement with Saniona to develop and commercialize SAN711 for neurological disorder indications.
Here's Why Acadia Pharmaceuticals ( ACAD ) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
